FTRE
NASDAQ
US
Fortrea Holdings Inc. - Common Stock
$9,45
▼ $-0,06
(-0,63%)
Vol. 846K
2
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$1.6B
ROE
-119,7%
Margine
-36,8%
D/E
193,97
Beta
1,75
52W
$4–$20
Consenso Wall Street
17 analisti · Apr 20264
Acquisto forte
6
Compra
6
Mantieni
1
Vendi
0
Vendita forte
58,8%
Rating Compra
Grafico dei Prezzi
Titoli simili
TXG
10X Genomics Inc
$2.1B
ADPT
Adaptive Biotechnologies Corp
$2.5B
AZTA
Azenta Inc
$1.5B
BLFS
BioLife Solutions Inc
$1.2B
PSNL
Personalis Inc
$706.9M
CTKB
Cytek Biosciences Inc
$645.7M
MLAB
Mesa Laboratories Inc
$433.5M
CYRX
Cryoport Inc
P/E 7,1
$480.7M
MRVI
Maravai LifeSciences Holdings Inc
$831.0M
NAUT
Nautilus Biotechnology Inc
$246.3M
Utili
Tasso di battuta: 50,0%
Prossimo report
Mag 11, 2026
Stima EPS: $0,07
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $0,07 | — | — |
| Dic 2025 | $0,16 | $0,09 | $-0,07 |
| Set 2025 | $0,15 | $0,12 | $-0,03 |
| Giu 2025 | $0,06 | $0,19 | +$0,13 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… | 2025-1… |
|---|---|---|---|---|---|---|
| Ricavi | — | $697.0M | $651.3M | $710.3M | $701.3M | $660.5M |
| Utile netto | — | -$61.2M | -$562.9M | -$374.9M | -$15.9M | -$32.5M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -95.0% | -95.0% | -95.0% | -95.0% | -119.7% | -119.7% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -52.8% | -37.6% | -37.6% | -37.6% | -36.8% | -36.8% |
| Gross Margin | 18.8% | 19.7% | 19.7% | 19.7% | 18.6% | 18.6% |
| D/E Ratio | 199.54 | 199.54 | 199.54 | 199.54 | 193.97 | 193.97 |
| Current Ratio | 1.02 | 1.02 | 1.02 | 1.02 | 1.00 | 1.00 |
Rapporti chiave
ROA (TTM)
-33,1%
P/S (TTM)
0,58
P/B
1,2
EPS (TTM)
$-11,24
Crescita ricavi 3A
-4,1%
52W High
$20,26
52W Low
$3,97
$3,97
Intervallo 52 settimane
$20,26
Salute finanziaria
Flusso di cassa libero
$121.6M
Debito netto
$941.4M
Liquidità
$174.6M
Debito totale
$1.1B
Aggiornato al Dic 31, 2025
Як FTRE виглядає на тлі конкурентів у Life Sciences Tools & Services?
Група порівняння: Small-cap Life Sciences Tools & Services ($300M+) · 25 компаній
Оцінка FTRE vs аналоги Life Sciences Tools & Services
P/E
—
▼
0%
sotto
peer
(32,5)
vs Peer
vs Settore
Valore equo
P/S
0,6
▼
85%
sotto
peer
(3,8)
vs Peer
vs Settore
Sottovalutato
P/B
1,2
▼
67%
sotto
peer
(3,7)
vs Peer
vs Settore
Sottovalutato
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,5%)
vs Peer
vs Settore
Rendimento basso
Прибутковість FTRE vs аналоги Life Sciences Tools & Services
ROE
-119,7%
▼
3561%
sotto
peer
(-3,3%)
vs Peer
vs Settore
Debole
Net margin
-36,8%
▼
292%
sotto
peer
(-9,4%)
vs Peer
vs Settore
Debole
Валова маржа
18,6%
▼
61%
sotto
peer
(48,0%)
vs Peer
vs Settore
Debole
ROA
-33,1%
▼
1172%
sotto
peer
(-2,6%)
vs Peer
vs Settore
Debole
Фінансове здоровʼя FTRE vs аналоги Life Sciences Tools & Services
D/E ratio
194,0
▲
431%
sopra
peer
(36,5)
vs Peer
vs Settore
Debito alto
Поточна ліквідність
1,0
▼
70%
sotto
peer
(3,4)
vs Peer
vs Settore
Liquidità bassa
Beta
1,8
▲
23%
sopra
peer
(1,4)
vs Peer
vs Settore
Più volatile
Радар фундаменталів FTRE
FTRE
Mediana peer
Industria
FTRE прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
FTRE vs аналоги: ключові метрики
Ultime notizie
Nessuna notizia correlata ancora